Codexis Q3 net loss widens to $34.9M; revenue ex-PAXLOVID falls 57% to $9.3M

CODEXIS, INC.

2023-Q3 EPS reported -$1.02 revenue$43,582,000

Net loss of $34.9M ($0.50/share) vs $10.0M loss ($0.15) in Q3 2022; adjusted loss $17.9M ($0.26) excludes restructuring/impairments.
Total revenue $9.3M, down 73% YoY including PAXLOVID; ex-PAXLOVID revenue down 57% to $9.3M.
Cash $74.6M; expects runway to positive cash flow around end of 2026.
Reaffirms FY2023 guidance: product revenue $30-35M (ex-PAXLOVID), R&D revenue $21-24M, gross margin 55-65%.
ECO Synthesis platform on track for gram-scale synthesis by year-end; dsRNA ligase wide availability in H2 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CODEXIS, INC. reported financial results for for the third quarter ended September 30, 2023.

Period: for the third quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On November 2, 2023, Codexis, Inc. announced its financial results for the quarter ended September 30, 2023.

View on SEC.gov

Browse all earnings releases →

CODEXIS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-23-269388

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.